Pełna treść
5/2022
Nusinersen odgrywa kluczową rolę w leczeniu dorosłych pacjentów z SMA typu 2 i 3
Data publikacji online: 2022/11/15
Plik artykułu
This is an Open Access journal, all articles are distributed under the
terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC
BY-NC-SA
4.0). License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to
copy
and redistribute the material in any medium or format and to remix, transform, and build upon
the
material, provided the original work is properly cited and states its license.